ArticlesDroplet Digital PCR (ddPCR)General Interest

Bispecific Antibodies and Cancer Immunotherapy

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.
READ MORE →
Develop an Immunotherapy in Augmented Reality
AppsArticlesDrug Discovery and Development

Develop an Immunotherapy in Augmented Reality

Every year cancer kills eight million people worldwide. By 2030, the number of annually diagnosed cases will exceed 21.7 million resulting in 13 million cancer deaths due to aging and population growth. Join the fight against cancer by embarking on a research mission to develop a personalized immunotherapy using augmented reality.
READ MORE →
Moving Forward with Immunotherapies for Cancer
ArticlesDrug Discovery and DevelopmentFeatured Stories

Moving Forward with Immunotherapies for Cancer

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.
READ MORE →